BCP-ALL blasts are not dependent on CD19 expression for leukaemic maintenance
J Weiland, D Pal, M Case, J Irving, F Ponthan, S Koschmieder, O Heidenreich, A von Stackelberg, C Eckert, J Vormoor, A Elder · Klinische Pädiatrie · 2016 · Heft 05
Bibliografische Angaben
Zusammenfassung
Introduction: The B-lymphocyte surface marker CD19 is the focus of attention for the development of immunotherapies due to its high expression on leukemic blasts and B-lineage specificity. The monoclonal antibody blinatumomab and chimeric antigen receptor modified T-cells targeting CD19 have shown early promise in clinical trials in the treatment of B cell precursor acute lymphoblastic leukaemia (BCP-ALL). However, the precise role of CD19 in leukaemic maintenance is unclear. Results: To investigate this we silenced CD19 expression using RNA interference in BCP-ALL cell lines and BCP-ALL primograft samples. Assa…
